Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIVI NASDAQ:CABA NASDAQ:MNOV NASDAQ:PYXS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$7.57-6.0%$10.45$6.20▼$75.00$14.95M0.73186,322 shs59,351 shsCABACabaletta Bio$1.74+1.8%$1.73$0.99▼$8.77$86.77M2.71.69 million shs1.67 million shsMNOVMediciNova$1.27$1.37$1.12▼$2.55$62.29M0.436,473 shs19,997 shsPYXSPyxis Oncology$1.19+1.7%$1.19$0.83▼$5.39$72.48M1.13730,333 shs303,414 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie-5.96%-21.31%-31.18%-2.95%+75.43%CABACabaletta Bio+1.75%+8.34%-25.96%+41.46%-77.95%MNOVMediciNova0.00%+0.79%-9.93%-5.22%-7.97%PYXSPyxis Oncology+1.71%+6.73%-11.19%+24.13%-59.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIVIBioVie0.9341 of 5 stars0.04.00.00.02.80.00.6CABACabaletta Bio1.5918 of 5 stars3.52.00.00.00.00.80.6MNOVMediciNova1.4676 of 5 stars3.82.00.00.00.00.80.0PYXSPyxis Oncology1.7316 of 5 stars3.41.00.00.01.80.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIVIBioVie 4.00Strong BuyN/AN/ACABACabaletta Bio 3.00Buy$14.43729.23% UpsideMNOVMediciNova 3.50Strong Buy$7.00451.18% UpsidePYXSPyxis Oncology 2.80Moderate Buy$9.00656.30% UpsideCurrent Analyst Ratings BreakdownLatest BIVI, PYXS, MNOV, and CABA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025MNOVMediciNovaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.006/11/2025CABACabaletta BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.005/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/16/2025CABACabaletta BioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $13.005/15/2025CABACabaletta BioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $25.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$25.35 per shareN/ACABACabaletta BioN/AN/AN/AN/A$3.12 per shareN/AMNOVMediciNova$1M62.29N/AN/A$1.07 per share1.19PYXSPyxis OncologyN/AN/AN/AN/A$2.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$32.12M-$79.10N/A∞N/AN/A-100.88%-78.49%8/21/2025 (Estimated)CABACabaletta Bio-$115.86M-$2.54N/AN/AN/AN/A-78.29%-65.68%8/6/2025 (Estimated)MNOVMediciNova-$11.04M-$0.23N/AN/AN/AN/A-20.77%-19.68%8/6/2025 (Estimated)PYXSPyxis Oncology-$77.33M-$1.59N/AN/AN/AN/A-57.49%-45.17%8/13/2025 (Estimated)Latest BIVI, PYXS, MNOV, and CABA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025CABACabaletta Bio-$0.67-$0.71-$0.04-$0.71N/AN/A5/15/2025Q1 2025PYXSPyxis Oncology-$0.29-$0.35-$0.06-$0.35N/AN/A5/13/2025Q1 2025MNOVMediciNova-$0.14-$0.06+$0.08-$0.06N/AN/A5/12/2025Q3 2025BIVIBioVie-$3.20-$1.50+$1.70-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/ACABACabaletta BioN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A9.319.31CABACabaletta BioN/A3.963.96MNOVMediciNovaN/A17.6617.66PYXSPyxis OncologyN/A7.757.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%CABACabaletta BioN/AMNOVMediciNova9.90%PYXSPyxis Oncology39.09%Insider OwnershipCompanyInsider OwnershipBIVIBioVie2.39%CABACabaletta Bio11.25%MNOVMediciNova13.60%PYXSPyxis Oncology10.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie101.86 million1.81 millionNo DataCABACabaletta Bio5050.74 million45.03 millionOptionableMNOVMediciNova1049.05 million42.38 millionOptionablePYXSPyxis Oncology6061.95 million55.38 millionOptionableBIVI, PYXS, MNOV, and CABA HeadlinesRecent News About These CompaniesPyxis Oncology Inc News (PYXS) - Investing.comJuly 8 at 9:45 AM | investing.comPyxis Oncology (NASDAQ:PYXS) Stock Price Up 3.6% - Time to Buy?July 8 at 3:33 AM | marketbeat.comPyxis Oncology Chief Financial, Operating Officer Pamela Connealy Retires >PYXSJuly 3, 2025 | marketwatch.comPyxis Oncology Appoints New Principal Financial OfficerJuly 3, 2025 | tipranks.comPyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 30, 2025 | globenewswire.comPyxis Oncology Insiders Lose Out As Stock Sinks To US$1.14June 19, 2025 | finance.yahoo.comPyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of "Moderate Buy" from BrokeragesJune 16, 2025 | marketbeat.comPyxis Oncology Reports Increased Losses Amidst Ongoing R&D InvestmentsMay 30, 2025 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Globus Medical (GMED) and Ramsay Health Care (OtherRMSYF)May 22, 2025 | theglobeandmail.comPyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | globenewswire.comPyxis Oncology to Participate in Two Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comNew Approaches to Tumor Targeting Are Driving the Next Wave of Oncology BreakthroughsMay 8, 2025 | baystreet.caPyxis Oncology reveals promising preclinical data for cancer drugApril 27, 2025 | investing.comPyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADCApril 25, 2025 | globenewswire.com5 Small Drug Stocks to Buy as Tariff-Related Uncertainty LoomsApril 23, 2025 | zacks.comTop Cancer Stocks to Buy to Boost Your Portfolio's HealthApril 16, 2025 | zacks.comPyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology ForumApril 2, 2025 | globenewswire.comPyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025March 25, 2025 | globenewswire.comStifel Nicolaus Keeps Their Buy Rating on Pyxis Oncology (PYXS)March 24, 2025 | markets.businessinsider.comRBC Capital Remains a Buy on Pyxis Oncology (PYXS)March 20, 2025 | markets.businessinsider.comPyxis Oncology reports FY24 EPS ($1.32), consensus ($1.09)March 18, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIVI, PYXS, MNOV, and CABA Company DescriptionsBioVie NASDAQ:BIVI$7.57 -0.48 (-5.96%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$7.41 -0.16 (-2.11%) As of 07/10/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Cabaletta Bio NASDAQ:CABA$1.74 +0.03 (+1.75%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$1.74 +0.00 (+0.06%) As of 07/10/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.MediciNova NASDAQ:MNOV$1.27 0.00 (0.00%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$1.27 0.00 (0.00%) As of 07/10/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.Pyxis Oncology NASDAQ:PYXS$1.19 +0.02 (+1.71%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$1.18 -0.01 (-0.84%) As of 07/10/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
